A Happier, Healthier You.
Semaglutide
Semaglutide is a glucagon-like peptide-1 (GLP-1) analog that was approved in 2017 as a treatment method for improving glycemic control in patients with Type 2 diabetes. More recently Semaglutide was approved by the FDA for non-diabetic weight loss.
Studies have demonstrated that Semaglutide reduced appetite, improved control of eating, and reduced food cravings in addition to improved glycemic control.
The greatest weight loss benefits were observed when Semaglutide is used in combination with lifestyle changes, such as improved diet and consistent exercise.
Frequently Asked Questions
GLP-1 is a hormone produced in the small intestine that stimulates insulin secretion and inhibits glucagon secretion, thereby lowering blood sugar. Semaglutide + B12 has demonstrated beneficial effects on glycemia, in addition to a host of other benefits.
Start with 0.25mL once weekly, increase to 0.5mL if needed/tolerated.
Semaglutide + B12 is a subcutaneous injection which is most commonly dosed at 0.25mL(0.5mg) to 0.5mL(1mg) once weekly. This dosing may be increased to 1mL(2mg) once weekly after one month of treatment if needed.
This medication is generally well-tolerated and can be dosed continuously without breaking treatment with no diminishing effects.
The most commonly reported side effects include nausea, vomiting, diarrhea, stomach pain, and constipation. The risk of serious side effects increases in patients with hypoglycemia, kidney problems, andrisk of allergic reactions.